Estradiol (17-beta Estradiol (E2))

Estradiol (17-beta estradiol) is the most potent naturally occurring estrogen in the human body. Molecular weight: 272.38 Da. CAS number: 50-28-2. During reproductive years, the ovaries produce 100-400 mcg of estradiol daily. After menopause, production drops by over 90%, which is what causes menopausal symptoms.

The term 'bioidentical' means the molecule is structurally identical to what the body produces. This distinction matters because older HRT formulations used conjugated equine estrogens (Premarin, derived from pregnant mare urine) and synthetic progestins (medroxyprogesterone acetate), which have different receptor binding profiles and metabolic effects. Modern HRT practice has largely shifted to bioidentical estradiol and bioidentical progesterone based on evidence showing better safety profiles.

The Women's Health Initiative (WHI) is the landmark study that shaped HRT prescribing for a generation. When initial results published in 2002 suggested increased cardiovascular and breast cancer risk, millions of women stopped HRT overnight. But the story turned out to be more complicated. The WHI enrolled women averaging age 63, many more than a decade past menopause. Subsequent analysis (JAMA, 2013, PMID: 24084921) showed that women aged 50-59 who received estrogen-alone therapy actually had reduced coronary heart disease, reduced breast cancer, and reduced all-cause mortality. The problem wasn't estrogen. It was starting estrogen too late, and the synthetic progestin used in the study.

The KEEPS trial (Annals of Internal Medicine, 2014, PMID: 25222550) specifically tested HRT in recently menopausal women (within 3 years of menopause) and found improvements in mood, sexual function, and bone density without increased cardiovascular risk. This confirmed the 'timing hypothesis': HRT started near menopause is beneficial; HRT started decades later may carry more risk.

Transdermal estradiol (patches, creams, gels) has become the preferred delivery method for most practitioners. The reason: oral estradiol undergoes first-pass hepatic metabolism, which increases production of clotting factors and C-reactive protein. Transdermal delivery bypasses the liver entirely, providing stable estradiol levels without these hepatic effects. A 2017 meta-analysis found that transdermal estradiol does not increase venous thromboembolism risk, while oral estrogen does.

Dosing depends on the goal. For systemic symptom relief (hot flashes, mood, bone protection), standard doses are 0.05-0.1 mg/day via patch or equivalent. For vaginal symptoms alone, low-dose local estradiol (vaginal cream, ring, or tablet) provides tissue-specific effects with minimal systemic absorption.

Women with an intact uterus must take progesterone alongside estradiol. Without progesterone, unopposed estrogen stimulates endometrial growth and increases the risk of endometrial cancer. Micronized progesterone (Prometrium, 100-200 mg at bedtime) is the bioidentical option most practitioners prefer, based on data from the French E3N study showing it carries less breast cancer risk than synthetic progestins.

Store estradiol products according to formulation: patches at room temperature, creams and gels at room temperature, oral tablets at room temperature protected from moisture.